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For many years the IFN-γ ex vivo ELISPOT has been a major assay for assessing human T-cell
responses generated by malaria vaccines. The ELISPOT assay is a sensitive assay, but an
imperfect correlate of protection against malaria. Monokine induced by gamma (MIG), or
CXCL9, is a chemokine induced by IFN-γ and has the potential to provide ampliﬁcation of the
IFN-γ signal. MIG secretion could provide a measure of bio-active IFN-γ and a functional IFN-γ
signalling pathway. We report that detecting MIG by ﬂow cytometry and by RT-PCR can be
more sensitive than the detection of IFN-γ using these methods. We also ﬁnd that there is little
inter-individual variability in MIG secretionwhen detected by ﬂow cytometry and that the MIG
assay may be used to estimate the amount of bio-active IFN-γ present. Measurement of MIG
alongside IFN-γ may provide a fuller picture of Th1 type responses post-vaccination.
© 2008 Elsevier B.V.
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1. Introduction
Malaria kills over one million people every year, the
majority of whom are children (Breman et al., 2001). Vaccina-
tion may offer one way of effectively treating or even eradi-
cating this disease.
Research into the pre-erythrocytic stage of the malaria
parasite's life cycle has shown thatmany factorsmaybe involved
in protection from malaria in humans. Antibodies, T-cells and
cytokines, particularly IFN-γ, have all been shown to associate
with protection against malaria, in both mice (García-López,
2001; Pinder et al., 2004; Vuola et al., 2005) and humans
(Schoﬁeld et al., 1987; Weiss et al., 1988; Renia et al., 1991;
Nussler et al., 1993; Khusmith et al., 1994; Reece et al., 2004).
IFN-γ measured by the ex vivo IFN-γ ELISPOT has been the
primary readout of immunogenicity for T-cell inducing vaccines
in clinical trials (Vuola et al., 2005; Bejon et al., 2006; Dunachie
et al., 2006). The ex vivo ELISPOT assay enables determina-
tionof thenumberof IFN-γ secreting cells but not thequantityof
IFN-γ secreted or the functionality of the cytokine. In general,
the vaccine regimens which induce high IFN-γ ex vivo ELISPOT
responses have been shown to induce greater protection
(Webster et al., 2005)and following vectored vaccines, the
IFN-γ ex vivo ELISPOT has been found to correlate with pro-
tection from malaria (Dunachie et al., 2006). Whilst IFN-γ is
involved in protection in somemalaria models (Meding et al.,
1990; Stevenson et al., 1990; Bruna-Romero et al., 2001), it is
likely that other factors are involved in human malaria and
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the ex vivo IFN-γ ELISPOT assay is not able to clearly measure
all the protective features of the immune response tomalaria
(Flanagan et al., 2003; John et al., 2004). An alternative
measure may be more sensitive and may correlate better
with protection from malaria.
The secretion of monokine induced by gamma (MIG: CXC
chemokine ligand 9 (CXCL9) has been examined as an alter-
native marker of immunogenicity (Brahmbhatt et al., 2002).
MIG, a member of the CXC subfamily of chemokines is an
inﬂammatory chemokine that is important in the recruitment
of activated T-cells to sites of infection. MIG enhances Th1 and
Th2 polarization, attracting Th1 cells and inhibiting Th2
migration. A strong MIG mediated Th1 response has been
shown to be important in protection from Trypanosoma cruzi
(Hardison et al., 2006). There are two features of the MIG
response that make it an attractive chemokine to measure.
Firstly, MIG is induced by IFN-γ, whichmay allow it to provide
a functional measure of IFN-γ activity (Farber, 1993). Secondly
MIG is produced following an ampliﬁcation of the IFN-γ
signal and may be easier to detect and a more sensitive
measure of bio-active IFN-γ than detecting IFN-γ directly
(Brice et al., 2001).
MIG is secreted by macrophages, monocytes, neutrophils,
APC, B cells and eosinophils (Whiting et al., 2004). However,
CD14+ cells which include monocytes and macrophages
are thought to comprise the majority of MIG secreting cells
(Loetscher et al., 1996; Brice et al., 2001). MIG secretion by
these cells is induced by IFN-γ and mediated via the JAK-STAT
signalling pathway (Sarkar et al., 2007). MIG secretion is
therefore an indication of a functional JAK-STAT signal from
the IFN-γ receptor. It has also been reported that MIG can be
induced by IFN-α in IFN-γ−/− mice, when IFN-α and IFN-γ are
both inhibited, MIG expression is completely absent (Maha-
lingam et al., 2001).
Antigen speciﬁc MIG secretion, detected by ELISA and ﬂow
cytometry, in two studies have reported MIG detection to be a
sensitive measure of immunogenicity (Brice et al., 2001;
Abramo et al., 2006). Brice et al. were able to demonstrate the
detection of malaria peptide speciﬁc MIG production in one
subject vaccinated with irradiated sporozoites. Our study of 12
subjects is the ﬁrst evaluation of MIG and IFN-γ detection
by ﬂow cytometry in the context of a phase I vaccine trial of a
recombinant viral vector vaccine. This study aimed to test the
ability of MIG as a sensitive marker of viral vectored recombi-
nant malaria vaccine that induces immunogenicity. The afore-
mentioned studies did not compare both MIG and interferon
gamma production directly using intracellular staining.
Therefore this study directly compared the sensitivity of
MIG and IFN-γ by intracellular staining and RT-PCR in the
context of recombinant malaria vaccines.
2. Methods
2.1. Subjects and vaccine regimens
Volunteers recruited for this malaria vaccine trial were
malaria-naive, male or female Caucasians aged 18–65 years.
Volunteers received six separate vaccinations administered
in three visits as described elsewhere (Thompson et al., 2008).
The ﬁrst and second immunisations consisted of one dose of
the viral vaccine fowlpox strain 9 (FP9) encoding thrombos-
pondin adhesive protein with a multi-epitope string (ME-
TRAP) (1×108 pfu) and one dose of the virosomal vaccine
PEV3A that includes cyclised peptides from the circumspor-
ozoite protein (CSP) and the apical membrane antigen 1
(AMA1) of Plasmodium falciparum. PEV3A was given as 0.5 ml
containing 50 mg of PEV301 (AMA-49) and 10 mg of PEV302
(UK39) in phosphate buffered saline (pH 7.4). The third
immunisation consisted of PEV3A given in conjunction with
one dose of the viral vaccine Modiﬁed Vaccinia virus Ankara
(MVA) encoding ME-TRAP (1.5×108 pfu). All the immunisa-
tions were given four weeks apart. The vaccine regimen
will be referred to as PFPFPM, P representing PEV3A, F repre-
senting FP9 encoding ME-TRAP, and M representing MVA
encoding ME-TRAP. Blood was analysed for CS and TRAP
speciﬁc immune responses before any vaccine was adminis-
tered (D0), seven days after the ﬁnal vaccination (V3+7) and
on the day of malaria challenge (DOC), which was 14 days
after the ﬁnal vaccination (V3+14). Further details of this trial
are reported elsewhere (Thompson et al., 2008).
Peripheral blood mononuclear cells (PBMC) were isolated
from buffy coats from healthy blood donors (National Blood
Service, Bristol) and used for the optimisation experiments.
2.2. PBMC separation
PBMC were separated using a density gradient. Blood was
collected from each volunteer into a heparin tube and
processed within 6 h of collection. Fifteen to thirty milliliters
of blood was layered onto 15 ml of lymphoprep (Axis-Shield,
Oslo, Norway) pre-aliquoted into leucosep tubes (Greiner-
Bio-One Laboratories, Friekenhausen, Germany). The leuco-
sep tubes were centrifuged and PBMC collected from just
above the lymphoprep. PBMC were washed twice with
Roswell park memorial institute media (RPMI) and counted
before use in the assays. PBMC obtained from the Blood
Donation Service (Bristol UK) were separated as described
above following 1/2 dilution with RPMI.
2.3. Stimulant peptides
One pool containing 57×20 mer peptides spanning the
whole of the TRAP protein was used at a concentration of
10 µg/ml. Another pool containing 23×9mer CD8+ T-cell viral
epitopes from Cytomegalovirus (CMV), Epstein Barr Virus
(EBV), and inﬂuenza, was used at a concentration of 10 µg/ml
(Good et al., 1993). These will be referred to as the CEF pool.
Puriﬁed protein derivative (PPD) was used at a concentration
of 10 µg/ml. Phytohaemagglutinin (PHA) and Staphylococcal
enterotoxin B (SEB) were used as positive controls at a con-
centration of 1 µg/ml.
2.4. Ex vivo IFN-γ ELISPOT assay
Fifty micro-liters of isolated PBMC (0.4×106 cells) and
50 µl of stimulant peptide were added to an ELISPOT plate
(MultiScreen-IP plates; Millipore, Watford, United Kingdom)
pre-coated the day before with 50 µl of IFN-γ capture
antibody (1-D1K; MabTech, Nacka, Sweden) at 10 µg/ml in
carbonate buffer (Sigma, Poole, UK) then blocked with 100 µl
of R10 (R10: RPMI 1640 with 10% fetal calf serum, 100 IU/ml
penicillin, 0.1 mg/ml streptomycin (all Sigma, Poole, UK), and
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2mM L-glutamine (GIBCO/Invitrogen, Paisley, UK)). The plates
were incubated for 18–20 h at 37 °C. After washing six times
with PBS-Tween (Sigma, Poole, UK), 50 µl of 1 µg/ml of
detector antibody (7-B6-1-Biotin Mabtech, Nacka, Sweden)
was added. Fifty micro-liters of 1/1000 Streptavidin con-
jugated with enzyme —ALP (Mabtech, Nacka, Sweden) was
added following another washwith PBS-Tween (Sigma, Poole,
UK). The plates were developed with a precipitating substrate
ALP kit (Bio-rad, Hercules, CA) according to the manufac-
turer's instructions. The plates were dried and read using an
AID ELISPOT reader (AID, Strassberg, Germany).
2.5. Intracellular staining (ICS)
Cryopreserved PBMC were thawed quickly and added to
1ml of R10with 25 U/ml benzonase nuclease (Novagen). Cells
were then dilutedwith a further 9ml of R10, washed once and
resuspended for counting (CasyCounter TT Schärfe System,
Reutlingen, Germany). Either 100 µl of 1×106 PBMC, or 50 µl
of 1×106 PBMC with 50 µl of 0.1 µg/ml anti-CD28 and anti-
CD49d antibodies (BD Pharmingen, Oxford, UK) were cul-
tured for MIG ICS analysis. Two million PBMC in 50 µl with
50 µl of 0.1 µg/ml anti-CD28 and anti-CD49d antibodies were
cultured for IFN-γ ICS analysis. Fifty micro-liters of stimulant
peptides were added to both assays. Unless otherwise stated
the cells were then incubated for 6 h at 37 °C before the
addition of 0.1 µg/ml Brefeldin A (BD Pharmingen, Oxford,
UK). The cells were then incubated at 37 °C for 6 h unless
otherwise stated.
Stains used were MIG ICS (CD14-FITC— clone M5E2), IFN-γ
ICS (CD3-PE-cy7 clone SK7), CD4 (APC-cy7 clone RPA-T4) and
CD8 (FITC clone SK1). 7AADwasused as a dead cell stain in both
the MIG and IFN-γ analysis.
Cells were analysed using a FACSCalibur ﬂow cytometer
(FACSCalibur, BD Biosciences). The MIG data is presented as
the percentage of MIG positive cells within the CD14+, 7AAD-
ve gate. Thirty thousand to ﬁfty thousand events were
collected, which ensured at least 1000 events in the MIG+
CD14+ 7AAD-ve gates in the positive controls were collected.
The IFN-γ data is presented as the percentage of IFN-γ+ cells
within the CD3+ 7AAD-ve gate. Seven hundred thousand
events were collected which ensured that at least 600 events
were collected in the IFN-γ+ CD3+ 7AAD-ve gates in the
positive controls. For the vaccine trial subjects the data is
presented as the number of cytokine (MIG or IFN-γ) positive
cells in the TRAP stimulated samples minus the number of
cytokine positive cells in the unstimulated media alone
sample. A positive result was determined by the sample
being over 3 standard deviations above themean of themedia
wells at the baseline time point.
2.6. Real-time RT-PCR
RNA extraction was carried out using the RNeasy Mini-kit
(Qiagen, Crawley, UK). Extractions were carried out according
to the manufacture's recommendations following a 12 h
incubation with peptides. Twelve hours has been reported
to detect early, mid and late gene expression in response to
antigen stimulation (Huang et al., 2001). Brieﬂy, cells were
lysed in 100 µl RNA Lysis Buffer (RLT) containing 10% β-
mercaptoethanol (BME). One hundred micro-litres of 70%
ethanol was added to each sample, which was then applied to
an RNeasy mini column. The columns were then washed 3
times and RNA eluted into 30 µl of RNase free water.
RNA was reverse transcribed to cDNA using Omniscript
reverse transcriptase (Omniscript kit, Qiagen, Crawley, UK)
with oligo-dT-primers (MWG Biotech, Milton Keynes, UK)
according to the manufacture's instructions.
Real time PCR was carried out using a Light Cycler (Roche).
PCRmaster mix consisted of 10 µl Quantitect (Qiagen Crawley,
UK) and 10 pmol of each primer (Forward and Reverse)
diluted with water. Nineteen micro-litres of master mix and
1 µl of cDNA template was added to each light cycler tube.
Primers were used:
HPRT (F 5′-TATGGACAGGACTGAACGTC-3′ and R 5′-CTACAAT
GTGATGGCCTCCC-3′), MIG (F-5′GCATCATCTTGCTGGTTCTGAT
TGG-3′, and R 5′-GCGACCCTTTCTCACTACTGGGGT-3′), IFN-γ
(F-5′ AGCCATCTCTGTCCTC-3′ and R 5′-TTCTGCTCTGACAACCT-
3′), FOXP3 (F-5′ CACTTACAGGCACTCCTCCAGGand R5′-CCACCG
TTGAGAGCTGGTGCAT), IFN-α (F 5′-AGCCATCTCTGTCCTC-3′
and R 5′-TTCTGCTCTGACAACCT-3′). PCR ampliﬁcation condi-
tions were: 94 °C—15 min, followed by 50 cycles of 94 °C—15 s,
60 °C—15 s and 72 °C—15 s.
The results are presented as the mRNA fold change of
the TRAP stimulated samples against the unstimulated media
alone samples.
2.7. Statistical analysis
IFN-γ, MIG and FoxP3 expression were normalised by
dividing copy number of gene by copy number of the house
keeping gene hypoxanthine phosphoribosyl transferase
(HPRT). Paired Student's t-test was used to analyse normally
distributed data and Wilcoxon rank sum or a Mann–Whitney
U test was performed on non-normally distributed data.
Spearman's test was used for correlation. The statistics were
calculated using SPSS for Windows Version 12.0.
3. Results
3.1. The increase in MIG mRNA expression is greater than the
increase in IFN-γ mRNA expression
PBMC from 10 volunteers vaccinated with the PFPFPM
regimen, were stimulated with TRAP peptides. Real-time RT-
PCR was used to quantify MIG and IFN-γ expression in the
stimulated and unstimulated cells from the pre-vaccination
time point (D0) and 7 days after the ﬁnal vaccination (V3+7).
The expression of IFN-γ and MIG were normalised to HPRT.
The median fold increase; TRAP stimulated against the media
alone, in IFN-γ expression at the V3+7 time point was 1.7
(Fig. 1A) compared to a median fold increase at the V3+7 time
point of 5.2 in MIG expression (Fig. 1B). A signiﬁcant differ-
ence was seen between the fold change in IFN-γ expression
and the fold change in MIG expression (Wilcoxon Signed
Ranks Test P=0.013) at this time point.
3.2. Optimisation of incubation time, before the addition of
brefeldin A for the MIG and IFN-γ ICS assays
MIG is secreted following binding of IFN-γ to its receptor
in monocytes and macrophages. The interferon signal is
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ampliﬁed in monocytes and macrophages, and MIG mRNA is
produced at a higher level than IFN-γ mRNA (Fig. 1).
Brefeldin A blocks proteins from being secreted. Brefeldin
A may therefore prevent IFN-γ from being secreted and thus
from inducing MIG. PBMC from 5 normal human donors were
stimulated with either a mixture of viral CD8+ T-cell epitopes
(CEF) (Fig. 2A) or PPD (Fig. 2B). The cells were incubated for 0,
2, 4, 6, 8 and 10 h before brefeldin Awas added, and incubated
for a further 18 h after brefeldin A was added.
A longer incubation time before the addition of brefeldin A
resulted in the detection of a higher number of MIG secreting
CD14+ cells. A signiﬁcantly higher percentage of CD14+ MIG+
cells were detected at 6 h and 8 h compared to 2 h (Student's
paired t-test P=0.034 for 2 and 6 h, P=0.049 for 2 and 8 h ) in
the CEF stimulated cells. A signiﬁcant increase was also seen
from 6 h to 8 h, (Student's paired t-test P=0.02) in the PPD
stimulated cells.
Optimisation tests were also carried out to determine the
optimal incubation time for detecting IFN-γ. PBMC from 9
normal human donors were selected and stimulated with CEF
(Fig. 2C) or PPD (Fig. 2D). No signiﬁcant differences were
detected between the early time pointswith either stimulation
(0 h–6 h). However a signiﬁcant decrease in the percentage of
IFN-γ secreting cellswasdetectedbetween4 and8h (P=0.042)
and 4 and 12 h (P=0.018), as well as between 6 and 8 h
(P=0.042) (Wilcoxon rank sumtest). FollowingPPDstimulation,
Fig. 1. (A) shows box and whisker plot of the MIG mRNA fold change; TRAP
stimulated against the media alone. The samples were tested at the pre-
vaccination time-point D0, and 7 days after the ﬁnal vaccination V3+7 (n=10).
The samples were incubated for 12 hours before mRNA was extracted. A 5.2
fold change was seen from D0 to the V3+7 time point. (B) shows a box and
whisker plot of IFN-γmRNA fold change; TRAP stimulated against the media
alone samples, at the pre vaccination time-point D0 and 7 days after the ﬁnal
vaccination V3+7. A fold change of 1.7 was seen from D0 to the V3+7 time
point. A signiﬁcant difference was seen between the fold change in IFN-γ
expression and the fold change in MIG expression (Wilcoxon Signed Ranks
Test P = 0.013).
Fig. 2. (A) MIG ICS response to CEF peptides. (B) MIG ICS response to PPD.
(C) IFN-γ ICS responses to CEF peptides. (D) IFN-γ ICS responses to PPD.
Optimization of the incubation time with CD8+ viral epitopes (CEF) (panels A
and C) and PPD (panels B and D) before addition of brefeldin A. Brefeldin A
was added at 2 hourly intervals after addition the antigens. Samples were
analysed after a further 18 h of incubation. The data is presented as the mean
percentage ofMIG+ cells±S.E (panels A and B) (n=5) and themeanpercentage
of IFN-γ+ cells±S.E (panels C and D) (n=9), with background media only
wells deleted. A signiﬁcant difference in the CEF stimulated samples (panel A)
was seen between 0 and 10 h, 2 and 6 h, and 2 and 8 h (P=0.002 for 0 and 10 h,
P=0.034 for 2 and 6 h, P=0.049 for 2 and 8 h, Student's paired T-test). A
signiﬁcant difference in the PPD stimulated samples (panel B) was seen
between 6 and 8 h (P=0.02 Student's paired T-test). A signiﬁcant difference
in IFN-γ productions following CEF stimulation (panel C) was seen between
4 and 8 h, 6 and 8 h, and 4 and 12 h (P=0.042 for 4 and 8 h, P=0.042 for 6 and
8 h, P=0.042 for 4 and 12 h, Wilcoxon signed rank test). A signiﬁcant differ-
ence in IFN-γ production was seen in the PPD stimulated samples (panel D)
was seen between 6 and 12 h (P=0.042 Wilcoxon signed rank test).
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a signiﬁcant drop in the percentage of IFN-γ was detected
between 6 and 12 h (P=0.042 Wilcoxon rank sum test). The
incubation time before the addition of brefeldin A for detecting
bothMIG and IFN-γ responses by ICS, was determined to be 6 h.
As brefeldin A may be toxic to cells (Pommepuy et al.,
2003), an experiment was carried out to determine the
optimum time of incubation after adding brefeldin A. Cells
from 5 normal human donors were incubated for 6 h with CEF
or PPD, then for a further 6 h or 18 h with brefeldin A. Both
MIG and IFN-γ production were analysed (data not shown).
No signiﬁcant difference was seen between the two incuba-
tion times (Student's paired t-test) in either cytokine.
3.3. Effect of co-stimulatory antibodies on the detection of MIG
Co-stimulatory antibodies anti-CD28 and anti-CD49d have
been shown to increase the sensitivity of the IFN-γ intracellular
staining assay (Waldrop et al., 1998). An experiment to test the
effect of co-stimulatory antibodies on the sensitivity of theMIG
ICS and IFN-γ ICS assay was carried out using PBMC from 6
normal human donors. Cells were incubated with CEF and
media alone, both with and without co-stimulatory antibodies.
No signiﬁcant differences (Student's paired t-test) in MIG
production between the samples with co-stimulatory antibo-
dies and the samples without co-stimulatory antibodies were
seen (Fig. 3), however a signiﬁcant difference in IFN-γ
production was detected in the CEF stimulated samples
between those with and without the co stimulatory antibodies
(P=0.043 Wilcoxon's-Signed Rank test).
The lack of increase in MIG secretion with the addition of
co-stimulatory molecules may indicate that the co-stimula-
tory molecules do not enhance IFN-γ secretion from the cell,
only intracellular IFN-γ production. In support of this theory,
Jennes et al. showed that co-stimulatory molecules did not
enhance the secretion of IFN-γ as detected by IFN-γ ELISPOT
(Jennes et al., 2002).
3.4. Dose–response curve of MIG to recombinant human IFN-γ
(rhIFN-γ)
It has been shown previously that MIG is induced by IFN-γ
(Farber, 1990, 1993; Amichay et al., 1996). PBMC from 6
different donors were stimulated with increasing concentra-
tions of rhIFN-γ. Stimulation with rhIFN-γ induced MIG
expression in a dose dependent manner (Fig. 4A and B). A
signiﬁcant number of MIG secreting cells can be detected
above background from as little as 0.01 ng/ml rhIFN-γ. The
standard deviation between the 6 individuals tested was
small and the ability of CD14+ cells to respond to IFN-γ in
PBMC cell culture is reproducible between individuals.
Fig. 2 (continued).
Fig. 3. Experiment to test whether the addition of co-stimulatory antibodies,
anti-CD28 and anti-CD49d, would increase the sensitivity of the MIG ICS assay.
PBMC from 6 normal human donors were stimulated with CEF peptides both
with andwithout the addition of co-stimulatory antibodies. BothMIG and IFN-γ
production were measured. The data is presented as the mean and standard
error of the percentage of IFN-γ positive cells within the CD3+ 7AAD-ve gate, or
the mean and standard error of the percentage of MIG positive cells within the
CD14+ 7AAD-ve gate. No signiﬁcant differences in MIG secretion were seen in
either CEFstimulatedormediaalone, betweenthesampleswithandwithout co-
stimulatory antibodies (Student’s paired T-test). A signiﬁcant difference in IFN-γ
productionwas detected in theCEF stimulated samples between thosewith and
without the co stimulatory antibodies (P= 0.043 Wilcoxon’s-Signed Rank test).
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3.5. Comparison of MIG ICS and IFN-γ intracellular staining
assays in volunteers vaccinated with a malaria vaccine
The optimised MIG ICS assay was then performed using
PBMC from 12 volunteers vaccinated with the PFPFPM
vaccine regimen. PBMC taken before the vaccination (D0),
7 days after the ﬁnal vaccination (V3+7) and 14 days after
the ﬁnal vaccination (V3+14) were stimulated with a pool of
TRAP peptides for a total of 12 h. The percentage of MIG+ cells
within the CD14+ population is shown in Fig. 5A. Fig. 5B
shows the antigen induced IFN-γ responses detected by ICS.
A positive response in both theMIG ICS and the IFN-γ ICSwas
deﬁned as more than 3 standard deviations above the mean
of media alone at baseline (D0). For the IFN-γ ICS this value
was 0.451% IFN-γ+ CD3+ cells, and for theMIG ICS it was 3.7%
MIG+CD14+ cells. The majority of the IFN-γ ICS responses
fell below the limits of detection of the assay (2 volunteers
were positive at V3+7 time point). Five positive responses
were detected by the MIG ICS assay at V3+7 and 2 positive
responses at V3+14. The percentage of MIG+ cells detected
by ICS above the mediawas also signiﬁcantly higher than the
percentage of IFN-γ + cells detected by ICS above the media
Fig. 4. Investigation into the amount of rhIFN-γ needed to induce a MIG ICS response. Increasing concentrations of rhIFN-γwere added to PBMC from 6 donors. The cells
were then incubated for 6 hours before and after the addition of brefeldin A. The data are presented as the mean percentage of MIG+ cells within the CD14+ population ±
standarddeviation (SD) (ﬁg.4A). A signiﬁcant difference inMIG secretionwas seenbetween themedia and0.01ng/ml rhIFN-γ (P=0.005 -Student’s paired T-test), andall the
higher concentrations of rhIFN-γ. Dotplots of onevolunteer’sMIGresponses to rhIFN-γare shown inﬁgure4B. Firstlydead cellswere excludedwith7AADdeadcellmarker.
Secondly the CD14+ cellswere then selected against forward scatter. TheCD14+population is shown in green inplot (i). The following plots (ii-vi) show theMIGproduction
within the CD14+ population. Responses to media (ii), 0.0001 ng/ml rhIFN-γ (iii), 0.001 ng/ml rhIFN-γ (iv), 0.01 ng/ml rhIFN-γ (v) and 0.1 ng/ml rhIFN-γ (vi) are shown.
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control at these time points (Wilcoxon Signed Rank Test
P=0.00039).
3.6. The ex vivo IFN-γ ELISPOT assay positively correlates with
the MIG ICS and MIG RT-PCR assay
An ex vivo ELISPOT assay for IFN-γ was also carried out
on these volunteers. Fig. 6 shows the positive correlation
between the ex vivo ELISPOT responses and the MIG ICS
responses at V3+7 (Spearman's correlation=0.793, 2-tailed
signiﬁcance P=0.002). The ex vivo IFN-γ ELISPOT also
positively correlated with MIG RT-PCR at the V3+14 time
point (Spearman's correlation=0.661, 2-tailed signiﬁcance
P=0.038) (data not shown). The MIG ICS assay did not
correlate with the IFN-γ ICS assay, and the MIG RT-PCR assay
did not correlate with the IFN-γ RT-PCR assay. This may be
due to the low level responses seen in the IFN-γ ICS and IFN-γ
RT-PCR assays.
4. Discussion
MIG is a chemokine produced largely by CD14+ monocytes
and macrophages, and is induced via the JAK-STAT pathway by
engagement of IFN-γ with it's receptor. It has not been shown
that antigen internalisationbyCD14+ cells causesMIG secretion
directly, although this remains to be tested. Detection of MIG
is therefore thought to be an indication of biologically active
IFN-γ, a functional IFN-γR and JAK1-STAT1 pathway. In this
paper we have shown that detecting MIG secretion by CD14+
cells using ﬂow cytometry can be a sensitive method for meas-
uring immune responses induced by vaccination, and that MIG
detection by ﬂow cytometry and RT-PCR can be more sensitive
than detecting IFN-γwith these methods.
We found that rhIFN-γ can induceMIG secretion by CD14+
cells in a dose dependent manner. The standard deviation
between the individuals tested was low which suggests that
the measurement of MIG by ICS may be a useful way to
estimate the amount of bioactive IFN-γ present in a culture.
A MIG ICS response signiﬁcantly above the background
could be detected when 0.01 ng/ml rhIFN-γ is added. In
contrast, the cut off for sensitivity used to detect IFN-γ by
ELISA in most reports is 0.1 ng/ml IFN-γ (Brahmbhatt et al.,
2002; Black et al., 2003; Pinder et al., 2004). PBMC from
naturally exposed volunteers stimulated with TRAP antigens
have been reported to induce above 0.02 ng/ml (John et al.,
2004), the amount of rhIFN-g shown to induce MIG is
therefore within the range seen in TRAP stimulated PBMC.
The MIG ICS assay may therefore be useful as a more sensitive
method for detecting IFN-γ secretion.
MIGproduction has previously been reported in response to
CMV, EBV and the circumsporozoite protein (CS) of P. falciparum
in healthy volunteers, as well as CFP10 and ESAT6 in
tuberculosis patients (Brice et al., 2001; Abramo et al., 2006).
Both of these studies showed MIG detection to be a sensitive
measure of immunogenicity. The sensitivity of the MIG ICS
compared to the IFN-γ ICS was tested here in volunteers
vaccinated with three PEV3A vaccinations in combinationwith
the FFM vaccine regimen encoding ME-TRAP (PFPFPM). More
Fig. 5. (A) shows the percentage of MIG+ cells within the CD14+7AAD-ve
gate in volunteers vaccinated with the PFPFPM vaccine regimen (n=12). V3+7
are shown in black and V3+14 are shown inwhite. The line indicates the cut of
for positivity, determined by 3 standard deviations above the mean of the
media wells at the baseline time point. Five of 12 positive responses detected
by the MIG ICS assay at V3+7 and 2/12 positive responses at V3+14. (B) shows
the percentage of IFN-γ+ cells within CD3+ 7AAD-ve gate in volunteers vacci-
natedwith the PFPFPMvaccine regimen. The responses at theV3+7 timepoint
are shown in black, andV3+14 are shown inwhite. The line indicates the cut of
for positivity, determined by 3 standard deviations above the mean of the
media wells at the baseline time point. Two of 12 of the volunteers induced a
positive IFN-γ ICS response at the V3+7 time point. The % of MIG+ cells
detected by ICS above the media is signiﬁcantly higher than the % of IFN-γ +
cells detected by ICS above the media control at these time points (Wilcoxon
Signed Ranks Test P=0.00039).
Fig. 6. Shows that the ex vivo ELISPOT responses (SFU per million PBMC)
signiﬁcantly correlated with % of MIG+ cells within the CD14+ 7AAD-ve gate at
V3+7 (Spearman’s correlation = 0.793, 2-tailed signiﬁcance P=0.002) (n=12).
39T.K. Berthoud et al. / Journal of Immunological Methods 340 (2009) 33–41
positive responseswere detectedwhenMIGwas analysedwith
ICS, than when IFN-γ was analysed by ICS. This indicates that
MIGmaybeexpressed and secretedat a higher level than IFN-γ.
The detection of MIG by ICS might therefore have a lower
threshold of sensitivity than the IFN-γ ICS assay. MIG produc-
tion was only induced in the antigen stimulated samples, not
the non-stimulated samples. This suggests that the MIG
production was antigen speciﬁc and probably induce by IFN-γ
originating from T-cells. It is however possible that the IFN-γ
mayhave been supplied by cells other thanT-cells suchasNKor
gammadelta T cells. Studies are currently being carried out to
investigate alternative sources for the IFN-γ.
IFN-α can also induce MIG expression (Mahalingam et al.,
2001). IFN-α RT-PCR was also carried out on the PFPFPM
vaccinated volunteers, no signiﬁcant difference was seen in
IFN-α expression between D0 and V3+7 indicating that the
MIG secretion was induced by IFN-γ.
As well as the potential sensitivity of theMIG ICS assay, the
detection of MIG eliminates the need for the use of expensive
co-stimulatory antibodies. Secondly, the MIG ICS assay can be
performed using frozen cells, which is useful for large-scale
vaccine trials where many of the biological samples are frozen
down. Thirdly as the population of MIG secreting CD14+ cells
is large, fewer cells are needed for the detection of a statis-
tically signiﬁcant response.
In these experiments, both the MIG ICS assay and MIG
RT-PCR assays were shown to positively correlate with the
ex vivo IFN-γ ELISPOT. A previous report analysing MIG
secretion in response to M. tuberculosis speciﬁc antigens in
tuberculosis patients and BCG vaccinated volunteers also
showed MIG secretion to correlate with the ex vivo IFN-γ
ELISPOT (Abramo et al., 2006).
Many approaches are being investigated with the aim of
identifying a sensitive method for immuno-monitoring in
vaccine trials, and vaccine trials on infants need to identify
immune responses in small volumes of blood. Using MIG as a
marker for antigen speciﬁc inﬂammatory immune responses
may increase sensitivity without the need for increasing the
volume of blood needed. The data presented here suggest that
ICS measurement of MIG could form a useful addition to
current methods used to detect vaccine induced T-cells.
References
Abramo, C., Meijgaarden, K.E., Garcia, D., Franken, K.L.M.C., Klein, M.R., Kolk,
A.J., Oliveira, S.C., Ottenhoff, T.H.M., Teixeira, H.C., 2006. Monokine
induced by interferon gamma and IFN-[gamma] response to a fusion
protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian
tuberculosis patients. Microbes and Infection 8, 45.
Amichay, D., Gazzinelli, R., Karupiah, G., Moench, T., Sher, A., Farber, J., 1996.
Genes for chemokines MuMig and Crg-2 are induced in protozoan
and viral infections in response to IFN-gamma with patterns of tissue
expression that suggest nonredundant roles in vivo. Journal of
Immunology 157, 4511.
Bejon, P., Mwacharo, J., Kai, O.K., Todryk, S., Keating, S., Lang, T., Gilbert, S.C.,
Peshu, N., Marsh, K., Hill, A.V.S., 2006. Immunogenicity of the candidate
malaria vaccines FP9 and modiﬁed vaccinia virus Ankara encoding the
pre-erythrocytic antigen ME-TRAP in 1–6 year old children in a malaria
endemic area. Vaccine 24, 4709.
Black, G.F., Weir, R.E., Chaguluka, S.D., Warndorff, D., Crampin, A.C.,
Mwaungulu, L., Sichali, L., Floyd, S., Bliss, L., Jarman, E., Donovan, L.,
Andersen, P., Britton, W., Hewinson, G., Huygen, K., Paulsen, J., Singh, M.,
Prestidge, R., Fine, P.E.M., Dockrell, H.M., 2003. Gamma interferon
responses induced by a panel of recombinant and puriﬁed mycobacterial
antigens in healthy, non-Mycobacterium bovis BCG-vaccinated Malawian
young adults. Clinical and Diagnostic Laboratory Immunology 10, 602.
Brahmbhatt, S., Hussain, R., Zafar, S., Dawood, G., Ottenhoff, T.H.M., Drijfhout,
J.W., Bothamley, G., Smith, S., Lopez, F.V., Dockrell, H.M., 2002. Human
T cell responses to peptides of the Mycobacterium leprae 45-kD serine-
rich antigen. Clinical and Experimental Immunology 128, 140.
Breman, J., Egan, A., Keusch, G., 2001. The intolerable burden of malaria: a
new look at the numbers. American Journal of Tropical Medicine and
Hygiene 64 iv–.
Brice, G.T., Graber, N.L., Hoffman, S.L., Doolan, D.L., 2001. Expression of the
chemokine MIG is a sensitive and predictive marker for antigen-speciﬁc,
genetically restricted IFN-[gamma] production and IFN-[gamma]-secreting
cells. Journal of Immunological Methods 257, 55.
Bruna-Romero, O., Gonzalez-Aseguinolaza, G., Hafalla, J.C.R., Tsuji, M., Nussenz-
weig, R.S., 2001. Complete, long-lasting protection against malaria of mice
primed and boosted with two distinct viral vectors expressing the same
plasmodial antigen. Proceedings of the National Academy of Sciences 98,
11491.
Dunachie, S.J., Walther, M., Epstein, J.E., Keating, S., Berthoud, T., Andrews, L.,
Andersen, R.F., Bejon, P., Goonetilleke, N., Poulton, I., Webster, D.P.,
Butcher, G., Watkins, K., Sinden, R.E., Levine, G.L., Richie, T.L., Schneider, J.,
Kaslow, D., Gilbert, S.C., Carucci, D.J., Hill, A.V.S., 2006. A DNA prime-
modiﬁed vaccinia virus ankara boost vaccine encoding thrombospondin-
related adhesion protein but not circumsporozoite protein partially
protects healthy malaria-naive adults against Plasmodium falciparum
sporozoite challenge. Infection and Immunity 74, 5933.
Farber, J., 1990. A macrophage mRNA selectively induced by {gamma}-
interferon encodes a member of the platelet factor 4 family of cytokines.
Proceedings of the National Academy of Sciences 87, 5238.
Farber, J.M., 1993. HuMig: a new human member of the chemokine family of
cytokines. Biochemical and Biophysical Research Communications 192, 223.
Flanagan, K.L., Mwangi, T., Plebanski, M., Odhiambo, K., Ross, A., Sheu, E.,
Kortok, M., Lowe, B., Marsh, K., Hill, A.V.S., 2003. Ex vivo interferon-
gamma immune response to thrombospondin related adhesive protein
in coastal kenyans: longevity and risk of plasmodium falciparum
infection. American Journal of Tropical Medicine and Hygiene 68, 421.
García-López, M.A., Sánchez-Madrid, F., Rodríguez-Frade, J.M., Mellado, M.,
Acevedo, A., García, M.I., Albar, J.P., Martínez, C., Marazuela, M., 2001.
CXCR3 chemokine receptor distribution in normal and inﬂamed tissues:
expression on activated lymphocytes, endothelial cells, and dendritic
cells. Laboratory Investigation 81, 409.
Good, M.F., Zevering, Y., Currier, J., Bilsborough, J., 1993. ‘Original antigenic
sin’, T cell memory, and malaria sporozoite immunity: an hypothesis for
immune evasion. Parasite Immunology 15, 187.
Hardison, J.L., Wrightsman, R.A., Carpenter, P.M., Lane, T.E., Manning, J.E.,
2006. The chemokines CXCL9 and CXCL10 promote a protective immune
response but do not contribute to cardiac inﬂammation following
infection with Trypanosoma cruzi. Infection and Immunity 74, 125.
Huang, Q., Liu, D., Majewski, P., Schulte, L.C., Korn, J.M., Young, R.A., Lander, E.S.,
Hacohen, N., 2001. The plasticity of dendritic cell responses to pathogens
and their components. Science 294, 870.
Jennes, W., Kestens, L., Nixon, D.F., Shacklett, B.L., 2002. Enhanced ELISPOT
detection of antigen-speciﬁc T cell responses from cryopreserved
specimens with addition of both IL-7 and IL-15—the Amplispot assay.
Journal of Immunological Methods 270, 99.
John, C.C.,Moormann, A.M., Sumba, P.O., Ofulla, A.V., Pregibon,D.C., Kazura, J.W.,
2004. Gamma interferon responses to Plasmodium falciparum liver-stage
antigen1 and thrombospondin-related adhesive protein and their relation-
ship to age, transmission intensity, andprotection againstmalaria. Infection
and Immunity 72, 5135.
Khusmith, S., Sedegah, M., Hoffman, S.L., 1994. Complete protection against
Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone
recognizing sporozoite surface protein 2. Infection and Immunity 62,
2979.
Loetscher, M., Gerber, B., Loetscher, P., Jones, S.A., Piali, L., Clark-Lewis, I.,
Baggiolini, M., Moser, B., 1996. Chemokine receptor speciﬁc for IP10 and
mig: structure, function, and expression in activated T-lymphocytes.
Journal of Experimental Medicine 184, 963.
Mahalingam, S., Chaudhri, G., Ling Tan, C., John, A., Foster, P.S., Karupiah, G.,
2001. Transcription of the interferon gamma (IFN-gamma )-inducible
chemokine Mig in IFN-gamma-deﬁcient mice. Journal of Biological
Chemistry 276, 7568.
Meding, S.J., Cheng, S.C., Simon-Haarhaus, B., Langhorne, J., 1990. Role of
gamma interferon during infection with Plasmodium chabaudi chabaudi.
Infection and Immunity 58, 3671.
Nussler, A.K., Renia, L., Pasquetto, V., Miltgen, F., Matile, H., Mazier, D., 1993. In
vivo induction of the nitric oxide pathway in hepatocytes after injection
with irradiatedmalaria sporozoites, malaria blood parasites or adjuvants.
European Journal of Immunology 23, 882.
Pinder,M., Reece,W.H.H., Plebanski,M., Akinwunmi, P., Flanagan,K.L., Lee, E.A.M.,
Doherty, T., Milligan, P., Jaye, A., Tornieporth, N., Ballou, R., McAdam, K.P.M.J.,
Cohen, J., Hill, A.V.S., 2004. Cellular immunity induced by the recombinant
40 T.K. Berthoud et al. / Journal of Immunological Methods 340 (2009) 33–41
Plasmodium falciparummalaria vaccine, RTS,S/AS02, in semi-immune adults
in The Gambia. Clinical and Experimental Immunology 135, 286.
Pommepuy, I., Terro, F., Petit, B., Trimoreau, F., Bellet, V., Robert, S., Hugon, J.,
Labrousse, F., Yardin, C., 2003. Brefeldin A induces apoptosis and cell
cycle blockade in glioblastoma cell lines. Oncology 64, 459.
Reece, W.H.H., Pinder, M., Gothard, P.K., Milligan, P., Bojang, K., Doherty, T.,
Plebanski, M., Akinwunmi, P., Everaere, S., Watkins, K.R., Voss, G.,
Tornieporth, N., Alloueche, A., Greenwood, B.M., Kester, K.E., McAdam,
K.P.W.J., Cohen, J. Hill, A.V.S., 2004. A CD4+ T-cell immune response to a
conserved epitope in the circumsporozoite protein correlates with
protection from natural Plasmodium falciparum infection and disease.
Nature Medicine 10, 406-410.
Renia, L., Marussig, M., Grillot, D., Pied, S., Corradin, G., Miltgen, F., Giudice, G.,
Mazier, D., 1991. In vitro activity of CD4+ and CD8+ T lymphocytes from
mice immunized with a synthetic malaria peptide. Proceedings of the
National Academy of Sciences 88, 7963.
Sarkar, S.A., Wong, R., Hackl, S.I., Moua, O., Gill, R.G., Wiseman, A., Davidson,
H.W., Hutton, J.C., 2007. Induction of indoleamine 2,3-dioxygenase by
interferon-{gamma} in human islets. Diabetes 56, 72.
Schoﬁeld, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R.,
Nussenzweig, V., 1987. [gamma] interferon, CD8+ T cells and antibodies
required for immunity to malaria sporozoites. Nature 330, 664–666.
Stevenson, M.M., Tam, M.F., Belosevic, M., van der Meide, P.H., Podoba, J.E.,
1990. Role of endogenous gamma interferon in host response to infection
with blood-stage Plasmodium chabaudi AS. Infection and Immunity 58,
3225.
Thompson, F.M., Porter, D.W., Okitsu, S.L., Westerfeld, N., Vogel, D., Todryk, S.,
Poulton, I., Correa, S., Hutchings, C., Berthoud, T., Dunachie, S., Andrews,
L., Williams, J.L., Sinden, R., Gilbert, S.C., Pluschke, G., Zurbriggen, R., Hill,
A.V.S., 2008. Evidence of blood stage efﬁcacy with a virosomal malaria
vaccine in a Phase IIa clinical trial. PLoS ONE 3, e1493.
Vuola, J.M., Keating, S., Webster, D.P., Berthoud, T., Dunachie, S., Gilbert, S.C.,
Hill, A.V.S., 2005. Differential immunogenicity of various heterologous
prime-boost vaccine regimens using DNA and viral vectors in healthy
volunteers. Journal of Immunology 174, 449.
Waldrop, S.L., Davis, K.A., Maino, V.C., Picker, L.J., 1998. Normal human CD4+
memory T cells display broad heterogeneity in their activation threshold
for cytokine synthesis. Journal of Immunology 161, 5284.
Webster, D.P., Dunachie, S., Vuola, J.M., Berthoud, T., Keating, S., Laidlaw, S.M.,
McConkey, S.J., Poulton, I., Andrews, L., Andersen, R.F., Bejon, P., Butcher,
G., Sinden, R., Skinner, M.A., Gilbert, S.C., Hill, A.V.S., 2005. Enhanced T
cell-mediated protection against malaria in human challenges by using
the recombinant poxviruses FP9 and modiﬁed vaccinia virus Ankara.
Proceedings of the National Academy of Sciences 102, 4836.
Weiss, W.R., Sedegah, M., Beaudoin, R.L., Miller, L.H., Good, M.F., 1988. CD8+
T cells (cytotoxic/suppressors) are required for protection in mice immu-
nizedwithmalaria sporozoites 10.1073/pnas.85.2.573. Proceedings of the
National Academy of Sciences 85, 573.
Whiting, D., Hsieh, G., Yun, J.J., Banerji, A., Yao, W., Fishbein, M.C., Belperio, J.,
Strieter, R.M., Bonavida, B., Ardehali, A., 2004. Chemokine monokine induced
by IFN-{gamma}/CXC chemokine ligand 9 stimulates T lymphocyte prolifera-
tion and effector cytokine production. Journal of Immunology 172, 7417.
41T.K. Berthoud et al. / Journal of Immunological Methods 340 (2009) 33–41
